Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
79.00
-3.15 (-3.83%)
Last updated: Apr 28, 2026, 3:59 PM HKT
30.58%
Market Cap 26.78B
Revenue (ttm) 54.70M
Net Income (ttm) -439.90M
Shares Out 325.98M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,824,910
Average Volume 896,698
Open 82.15
Previous Close 82.15
Day's Range 78.00 - 86.00
52-Week Range 52.25 - 206.00
Beta n/a
RSI 36.40
Earnings Date Mar 26, 2026

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology;... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 354
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2659
Full Company Profile

Financial Performance

In 2025, HKG:2659's revenue was 49.16 million, an increase of 697.99% compared to the previous year's 6.16 million. Losses were -395.30 million, 8.47% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.